Streetbeat News

Stock Prices

CRBP

Corbus Pharmaceuticals (NASDAQ:CRBP) reported a Q2 EPS of $(0.90), beating the analyst estimate of $(1.26) by 28.57%. This represents a 56.1% improvement over the $(2.05) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:15 pm

CSTL

Castle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and increased its FY24 revenue guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:15 pm

CMPX

Compass Therapeutics (NASDAQ:CMPX) has completed patient enrollment for its COMPANION-002 Phase 2/3 trial of CTX-009 in combination with paclitaxel for biliary tract cancer. The company also approved an Investigator Sponsored Trial (IST) of CTX-009 in the first-line setting for BTC patients.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:14 pm

RMCF

Rocky Mountain Chocolate Factory Inc. (NASDAQ:RMCF) announced a $2.2 million private placement of 1.25 million shares at $1.75 per share, a 15% premium to the closing stock price on August 5, 2024. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:13 pm

SPY

Jim Cramer suggests that a Trump presidency could be beneficial for income earners and investors, citing potential tax cuts. However, there are concerns about increased tariffs, inflation, and higher mortgage rates. The SPDR S&P 500 ETF Trust (SPY) rose 0.90% despite recent sell-offs.

Portfolio Pulse from Shanthi Rexaline

August 06, 2024 | 12:13 pm

TARA

Protara Therapeutics (NASDAQ:TARA) reported a Q2 EPS of $(0.45), beating the analyst estimate of $(0.80) by 43.75%. This represents a 55% improvement over the $(1.00) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:13 pm

RXST

RxSight Inc (NASDAQ:RXST) reported strong Q2 sales, beating analyst estimates and raising its FY24 revenue forecast. Despite this, shares fell 2.4% as analysts lowered their price targets.

Portfolio Pulse from Avi Kapoor

August 06, 2024 | 12:12 pm

DAVE

Dave shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm

EQ

Equillium, Inc. announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). The IDMC recommended the continuation of the trial based on safety and efficacy assessments. This triggers a 90-day period for Ono Pharmaceutical Co., Ltd. to exercise its option to acquire Equillium's rights to itolizumab for JPY 5 billion plus potential milestone payments.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm

FXI

TSLA

Tesla is recalling 1,683,627 cars in China, as reported by Bloomberg citing CCTV.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm